{'fraction_non_alphanumeric': 0.031203566121842496, 'fraction_numerical': 0.01337295690936107, 'mean_word_length': 5.299065420560748, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Barriers to participating in an HIV vaccine trial: a systematic review

Human immunodeficiency virus (HIV) exacts a heavy toll in terms of morbidity and mortality. Education programs stressing preventative methods have managed to slow the spread of HIV infection in some regions [1]. However, an estimated 15 000 new individuals are infected each day. Highly active antiretroviral therapy (HAART), despite its proven benefits, remains too costly and complex for the majority of HIV-infected people, 90% of whom live in developing countries [2]. Under these circumstances, an effective preventative vaccine may represent the best hope for reversing the growing HIV pandemic.